PDE4A and post-traumatic stress disorder: However, to date, testing in PTSD-relevant models is restricted to pan-PDE4 inhibitors, which have limited clinical utility owing to dose-dependent side effects of nausea and emesis, attributed to inhibition of PDE4D (Giembycz, 2002).